Background: There are increasing reports of paradoxical psoriasiform diseases sec-
| INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic inflammatory intestinal
condition caused by dysregulation of the immune response in the gastrointestinal mucosae and comprises two principal types: Crohn's disease (CD) and ulcerative colitis (UC). Tumour necrosis factor-a (TNF-a) is a proinflammatory cytokine that is highly upregulated in the mucosa of IBD patients and likely plays a key role in the pathogenesis of IBD. [1] [2] [3] Anti-TNF agents such as infliximab and adalimumab are therapeutic options for patients with IBD who have not benefitted from conventional therapy. [4] [5] [6] Moreover, recent trials have shown that early initiation of anti-TNF agents in patients with CD leads to superior clinical outcomes in terms of less disability and fewer surgeries and hospitalisation compared to conventional therapy alone. 7, 8 As the use of anti-TNF agents increases for treatment of IBD, renewed concern about adverse events of the treatment is also rising. Among these negative side effects, paradoxical psoriasiform skin lesions have been frequently reported to develop after anti-TNF treatment, [9] [10] [11] [12] [13] [14] [15] [16] although anti-TNF agents are also used to treat psoriasis itself. 17, 18 Although it is reported that up to 37% of patients with IBD who develop skin adverse events due to anti-TNF agents must stop using the drugs to control these side effects, 16, 19, 20 proper evidence-based guidelines to manage these lesions are lacking due to insufficient data on these phenomena. The incidence rate, clinical course and exact pathophysiology of paradoxical development of psoriasis in patients with IBD receiving anti-TNF agents are not yet known. There have not been any studies that describe the actual risk of paradoxical psoriasis secondary to anti-TNF agents in patients
with IBD compared to a control group.
The aims of this study were to determine the risks of paradoxical psoriasiform diseases secondary to anti-TNF agents in patients with IBD compared to those with IBD who did not receive those agents.
In addition, we sought to find the related risk factors for development of the skin lesions with subgroup analyses.
2 | ME TH ODS
| Data collection
This was a population-based retrospective cohort study using the ies, it is difficult to differentiate the patients with existing psoriasiform diseases completely. We did our best to rule out the influence of those patients by setting the 1-year washout period.
After that, the patients were classified into three groups: (1) IBD patients who had not received any anti-TNF agent during the study period, (2) IBD patients who received any anti-TNF agent for less than 6 months, and (3) IBD patients who received any anti-TNF agent for longer than a combined total of 6 months.
| Definitions
We defined the anti-TNF group as those who had been treated with infliximab and adalimumab for longer than 6 months from January 2007 to December 2016 and who underwent a 1-year washout period with no history of any psoriasiform disease prior to January 2008. During this study period, infliximab and adalimumab were the only two anti-TNF agents that were approved to treat IBD patients in Korea. When the ICD-10 code for psoriasiform diseases was identified before starting anti-TNF agents in the anti-TNF group, these patients were removed from the analysis. The control group was selected with a ratio of two controls per one anti-TNF case from IBD patients who had not been treated with any anti-TNF agent during the same period, with a 1-year washout period of no history of any psoriasiform disease; frequency matching with the anti-TNF group was performed with regard to age and sex.
The outcome of interest was new onset or relapse of psoriasiform disease, including psoriasis, palmoplantar pustulosis, and psoriatic arthritis. In both anti-TNF and control groups, patients with paradoxical psoriasiform diseases were defined as those who had at least two hospital visits due to the aforementioned diseases as principal diagnosis. In case of the anti-TNF group, the outcomes were counted when they were developed while using anti-TNF agents, whereas all outcomes that occurred during or after the use of anti-TNF agents were included in sensitivity analysis. the patients who received intestinal resection representing the severity of disease was significantly higher in the anti-TNF group compared to the control group (16.5% vs 4.8%, P < 0.001).
| Risks of paradoxical psoriasiform diseases
The incidence rate of psoriasis was 36.8 per 10 000 person-years in the total IBD patients using anti-TNF agents and 14.5 per 10 000 person-years in those not using anti-TNF agents ( 
| Sensitivity analysis
In the sensitivity analysis evaluating the risk of psoriasiform diseases during or after the anti-TNF treatment, the risk of all three types of psoriasiform diseases were significantly increased in the anti-TNF 
| DISCUSSION
In this study, the incidence rate of paradoxical psoriasis in patients with IBD treated with anti-TNF agents was 36.8 per 10 000 personyears, which was significantly greater than the patients with IBD not treated with anti-TNF agents (14.5 per 10 000 person-years). To the best of our knowledge, this is the first study comparing paradoxical psoriasis of anti-TNF agents with those of controls (IBD patients who had never received anti-TNF agents). The rates of psoriatic arthritis, a type of inflammatory arthritis developing in patients with psoriasis, and palmoplantar pustulosis were also significantly higher in IBD patients using anti-TNF agents than in those not using them.
In the subgroup analysis, male and younger (10-39 years) patients have significantly higher risks of palmoplantar pustulosis. Psoriatic arthritis was more highly developed in older (>40 years) patients.
This side effect is not to be ignored, and clinicians should consider this possibility when prescribing anti-TNF agents.
Previous studies have reported the estimated incidence of paradoxical psoriasis in IBD patients receiving anti-TNF agents. Adjusted by age, sex, insurance type, diabetes, hypertension, chronic obstructive pulmonary disease, chronic kidney disease, liver cirrhosis, ischaemic heart disease, heart failure, and the use of steroid, 5-aminosalicylic acid and other immunosuppressants.
only one comparative study that reported a 0.3% incidence rate of psoriasis in patients receiving anti-TNF agents and none in the comparison cohort. 29 We defined the operational definition for the anti-TNF group as IBD patients who had been treated with infliximab or adalimumab for longer than 6 months. Once the anti-TNF agents are started, these tend to be used for a relatively long time to maintain remission state of IBD. And in the Korea National Health Insurance situation, short term users of anti-TNF could appear because the insurance coverage is difficult if it is judged that there is no response from the anti-TNF agents. So, we decided the threshold of 6 months of using anti-TNF agents to detect the true anti-TNF users more precisely. As expected, the number of patients who received any anti-TNF agents for less than 6 months was quite low compared to the anti-TNF group.
Other investigated psoriasiform diseases including palmoplantar pustulosis and psoriatic arthritis were also more highly developed in IBD patients treated with anti-TNF agents. In our study, the risk of new-onset psoriasiform diseases after anti-TNF use did not increase abruptly after initiation or after a certain cumulative dose threshold.
Interestingly, the risk of palmoplantar pustulosis showed the biggest increase among three psoriasiform diseases, especially in male and younger patients. Palmoplantar pustulosis is characterised by grouped pustules on erythematous patches exclusively localised on palms and soles and has been described as a subtype of localised psoriasis before. However, now it is considered a separate entity apart from psoriasis because palmoplantar pustulosis does not progress to generalised psoriasis and has its unique clinical presentation. [30] [31] [32] Previous studies reported that palmoplantar pustulosis was one of the most frequent dermatological complications of anti-TNF therapy in IBD patients and was identified as being more common among current or former smokers with IBD. 9, 14, 28 Considering that most smokers are male in Korea, it can be explained why palmoplantar pustulosis was more developed in male patients. However, we
were not able to get the information about smoking status from this database.
Subgroup analyses were performed to distinguish factors predicting psoriasiform diseases induced by anti-TNF agents. We found that IBD patients treated with infliximab were more likely to develop paradoxical psoriasiform diseases, although the use of adalimumab did not showed significant increases in the incident psoriasiform diseases. However, the number of the patients who were treated with adalimumab was too small to establish this finding. There were a few studies to compare these two anti-TNF agents regarding incidence of skin reaction following their initiation. A single-centre study showed that IBD patients on adalimumab developed more psoriasiform rash than those on infliximab and had higher need for F I G U R E 2 Kaplan-Meier analyses of cumulative incidence of psoriasiform diseases in IBD patients with or without anti-TNF agents. A, Cumulative incidence of psoriasis. B, Cumulative incidence of palmoplantar pustulosis. C, Cumulative incidence of psoriatic arthritis treatment discontinuation. 33 On the contrary, the other study demonstrated that there was no significant difference of psoriasis development between them. 27 Based on previous results that the type of agent does not matter and switching to different agents often shows recurrence or persistence of psoriasis, the inherent structure of each antibody does not seem to be responsible for this reaction. 16, 17, 19, 20, 34 Although the pathogenesis of this paradoxical reaction is not fully understood, some possible explanations have been proposed.
One possible hypothesis is that inhibition of TNF-a by monoclonal antibody drugs induces interferon-a (IFN-a) overproduction by plasmacytoid dendritic cells, which is followed by T-cell activation and increased TNF-a production. 35, 36 Indeed, this hypothesis was supported by skin biopsies in which IFN-a protein expression increased in patients with anti-TNF-induced psoriasis. 9 In addition, the role of response. 9 However, these results were mainly based on CD patients, and more effort should be made to determine the exact underlying pathways.
This study had some limitations that were inevitable due to the inherent nature of claims-based studies. First, some misclassification of the disease might be present because coding and keying errors can exist in the National Health Insurance claims database. However, this coding system was shown to be fairly accurate for analysis by validation in previous studies. [37] [38] [39] Furthermore, the IBD patients treated with and without anti-TNF agents also had equal opportunities for coding errors, which should not lead to significant bias to the results. Second, IBD patients with severe disease could preferentially be allocated to the group treated with anti-TNF agents, and it cannot be excluded that those patients have a greater tendency to experience psoriasis. To overcome this, we compared the incidences of psoriasiform diseases before using anti-TNF agents between the control and anti-TNF groups, which was not significantly different (data not shown). Third, we were unable to evaluate the known risk factors for development of cutaneous adverse events such as the cumulative dose of anti-TNF agents, smoking or high body mass index because the database does not include those kinds of information. 40 Also, no data regarding duration or location of IBD could be obtained. However, these factors did not appear to be associated with the occurrence of adverse skin lesion. 41 Finally, no information on the detailed outcome of paradoxical skin reactions was available in the National Health Insurance claims database. Despite these shortcomings, we demonstrated the significant risks of paradoxical psoriasiform diseases secondary to the anti-TNF treatment compared to the age-and sex-matched controls not receiving anti-TNF agents using a large cohort.
In conclusion, use of anti-TNF agents in patients with IBD was associated with paradoxically new onset or aggravated psoriasis. The risk of this adverse effect is almost two times greater than that in IBD patients who had never been prescribed any anti-TNF agents.
Among psoriasiform diseases, the risk of palmoplantar pustulosis showed the biggest increase particularly in male and younger patients. Clinicians should inspect paradoxical psoriasiform diseases carefully when prescribing anti-TNF agents to IBD patients. To characterise the predictive factors for this phenomenon, further prospective cohort studies are required.
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